Avidity biosciences announces positive topline phase 1/2 fortitude™ data demonstrating consistent improvement across multiple functional measures compared to placebo in del-brax treated fshd participants

-- unprecedented data from fortitude™ dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and pros as well as rapid and significant reduction in biomarkers -- -- data support planned accelerated approval bla submission in h2 2026 -- -- data being presented at the 32nd annual fshd society international research congress (irc); investor and analyst webcast event today, monday, june 9 at 8:00 a.m. et -- san diego , june 9, 2025 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™) to profoundly improve people's lives, today announced positive topline data from the dose escalation cohorts of the delpacibart braxlosiran (del-brax) phase 1/2 fortitude™ program in facioscapulohumeral muscular dystrophy (fshd).
RNA Ratings Summary
RNA Quant Ranking